You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023204019
Dec 202370012
Jan 202451010
Feb 20249807
Mar 202492014
Apr 20249604
May 20245609
Jun 202458012
Jul 20246401
Aug 2024116012
Sep 202414005
Oct 202498010
Nov 2024160016
Dec 20248205
Jan 2025120019
Feb 20253804
Mar 20254030
Apr 2025009
May 2025007
Jun 2025004
Total15470209